Drug Trial Radar · NCT07223671
Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Dec 31, 2025
Primary completion
Feb 19, 2026
Study completion Mar 19, 2026
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study if to evaluate the effect of Repotrectinib on the drug levels of transporter and CYP P450 probe substrates in healthy adult participants.
Conditions
- Healthy Volunteers
Interventions
RepotrectinibDrug
Specified dose on specified days
MetforminDrug
Specified dose on specified days
DigoxinDrug
Specified dose on specified days
RosuvastatinDrug
Specified dose on specified days
BupropionDrug
Specified dose on specified days
FlurbiprofenDrug
Specified dose on specified days
OmeprazoleDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration of AUC (0-T) of Probe Substrate With RepotrectinibTime frame: Up to approximately Day 17 post dose
- Cohort 1: AUC (0-T) of Probe Substrate Without RepotrectinibTime frame: Up to approximately Day 17 post dose
- Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Probe Substrate With RepotrectinibTime frame: Up to approximately Day 17 post dose
- Cohort 1: AUC(INF) of Probe Substrate Without RepotrectinibTime frame: Up to approximately Day 17 post dose
- Cohort 1: Maximum Observed Plasma Concentration (Cmax) of Probe Substrate With RepotrectinibTime frame: Up to approximately Day 17 post dose
- Cohort 1: Cmax of Probe Substrate Without RepotrectinibTime frame: Up to approximately Day 17 post dose
- Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to 48 Hours Post Dose (AUC (0-48)) of Metformin With RepotrectinibTime frame: Up to approximately Day 17 post dose
- Cohort 1: AUC (0-48) of Metformin Without RepotrectinibTime frame: Up to approximately Day 17 post dose
- Cohort 1: Renal Clearance (CLR) of Metformin in UrineTime frame: Up to approximately Day 16 post dose
- Cohort 2: AUC (0-T) of Probe Substrate With RepotrectinibTime frame: Up to approximately Day 17 post dose
- Cohort 2: AUC (0-T) of Probe Substrate Without RepotrectinibTime frame: Up to approximately Day 17 post dose
- Cohort 2: AUC (INF) of Probe Substrate With RepotrectinibTime frame: Up to approximately Day 17 post dose
- Cohort 2: AUC (INF) of Probe Substrate Without RepotrectinibTime frame: Up to approximately Day 17 post dose
- Cohort 2: Cmax of Probe Substrate With RepotrectinibTime frame: Up to approximately Day 17 post dose
- Cohort 2: Cmax of Probe Substrate Without RepotrectinibTime frame: Up to approximately Day 17 post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Local Institution - 0001
Daytona Beach, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.